

CME, ABIM MOC, CE Credit Request Form

Atopic Dermatitis: You Can't Improve What You Don't Measure

Live Symposium – Wednesday, November 14, 2018

To receive CME/CE credit, you must complete all of this form and the evaluation form and turn them in to the CME Outfitters staff on your way out of the ballroom. Or you can fax it to: 614.448.4536. A certificate or statement of credit will be emailed to you within 4–6 weeks.

PLEASE PRINT CLEARLY (Form must be filled out completely to process CME, ABIM MOC, CE credit)

First Name, MI, Last Name: _____

Degree: MD DO RN NP
 PA PharmD RPh Other: _____

Specialty: Dermatology Allergy Internal Medicine Family Medicine Other: _____

Complete mailing address: _____

City: _____ State: _____ Zip: _____

Business Phone: _____ Fax: _____

Email (certificate or statement of credit will be emailed): _____

Type of CE credit requested: CME/Physicians (max. 1.5 _____) ABIM MOC (1.5) Others (1.5 CME Attendance Certificate)

How did you learn about this continuing education activity?

Faculty Flyer Email Phone call Text message Social Media Colleague Other: _____

As a result of my participation in this live symposium, I will commit to:

- Utilize the Hanifin Rajka criteria and/or the American Academy of Dermatology (AAD) criteria as an aid to diagnose AD. y n
- Integrate the Patient Oriented Eczema Measure (POEM) assessment scale into my clinical practice. y n
- Document tools used and the results of clinical assessments in my patients' charts. y n

CME, ABIM MOC, CE Activity Evaluation

Atopic Dermatitis: You Can't Improve What You Don't Measure

Live Symposium – Wednesday, November 14, 2018

To receive CME/CE credit, you must complete all of this form and the Credit Request Form and turn them in to the CME Outfitters staff on your way out of the ballroom. Or you can fax it to: 614.448.4536. A certificate or statement of credit will be emailed to you within 4-6 weeks.

Strongly Agree **Agree** **Neutral** **Disagree** **Strongly Disagree**

- | | | | | | |
|--|---|---|---|---|---|
| <p>1. The course met the stated objective(s):</p> <ul style="list-style-type: none"> • Utilize the Hanifin Rajka criteria and/or the American Academy of Dermatology (AAD) criteria to aid in the diagnosis of AD in clinical practice. • Integrate the Patient Oriented Eczema Measure (POEM) assessment scale into clinical practice to determine and track disease severity and response to treatment. • Document the use of tools and results of clinical assessments in patients' charts. <p>2. This activity helped me to have a better understanding of the topic(s).</p> <p>3. This activity assisted me to consider using the information in a different way to improve my practice.</p> <p>4. This activity provided me with resources I can use in my daily practice or with my patients.</p> <p>5. This activity will support my routine clinical practice to deliver evidence-based best practice that improves patient health outcomes.</p> <p>6. Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor):</p> | 5 | 4 | 3 | 2 | 1 |
| <ul style="list-style-type: none"> • Utilize the Hanifin Rajka criteria and/or the American Academy of Dermatology (AAD) criteria to aid in the diagnosis of AD in clinical practice. | 5 | 4 | 3 | 2 | 1 |
| <ul style="list-style-type: none"> • Integrate the Patient Oriented Eczema Measure (POEM) assessment scale into clinical practice to determine and track disease severity and response to treatment. | 5 | 4 | 3 | 2 | 1 |
| <ul style="list-style-type: none"> • Document the use of tools and results of clinical assessments in patients' charts. | 5 | 4 | 3 | 2 | 1 |
| 2. This activity helped me to have a better understanding of the topic(s). | 5 | 4 | 3 | 2 | 1 |
| 3. This activity assisted me to consider using the information in a different way to improve my practice. | 5 | 4 | 3 | 2 | 1 |
| 4. This activity provided me with resources I can use in my daily practice or with my patients. | 5 | 4 | 3 | 2 | 1 |
| 5. This activity will support my routine clinical practice to deliver evidence-based best practice that improves patient health outcomes. | 5 | 4 | 3 | 2 | 1 |

Speaker	Content	Clinical Relevance	Teaching Strategies	Level of Expertise
Zelma C. Chiesa Fuxench, MD, MSCE (Chair)	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Scott Feldman, MD, PhD	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Stephen D. Hess, MD, PhD	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

7. How many years have you been in practice? 0 years 1-5 years 6-10 years 11-20 years 20+ years
8. Will you change the way you practice based on this activity? y n
If no, please state reasons: _____
9. Do you feel the activity was balanced and objective? y n
If no, please state reasons: _____
10. Do you feel the activity was free of commercial bias? y n
11. Approximately what percent of this content was NEW to you? 25% 50% 75% This was all new information to me.
12. Approximately how many patients do you see with atopic dermatitis each month?
 0 1-5 6-10 11-15 16-20 21-25 26-50 More than 50
13. As compared to other CME activities you have participated in the past six months, do you believe this activity:
 Increased your knowledge Will improve patient outcomes in your practice
14. In the past 6 months, how many CME programs have you participated in? 1-4 5-10 11-15 More than 15
15. What was the most useful information you gained from this activity? _____

16. Suggested topics for future activities: _____

17. General comments/suggestions: _____

Thank you for your feedback. Your comments will be reviewed carefully and ultimately used to guide the development of our future continuing education activities.

Pre-Survey

Atopic Dermatitis: You Can't Improve What You Don't Measure

Live Symposium – Wednesday, November 14, 2018

Participants are required to complete the pre-survey and post-test to assess their achievement of the educational objectives for this activity. You must complete both this pre-survey and post-test as well as the evaluation and credit request form to receive credit.

First Name, MI, Last Name: _____

1. How confident are you in your ability to utilize the Hanifin and Rajka criteria and/or the AAD criteria to aid in the diagnosis of AD in clinical practice?
 - A. Extremely confident
 - B. Confident
 - C. Somewhat confident
 - D. Not confident at all
2. Which of the following best characterizes a patient with 3 of the major criteria of the Hanifin and Rajka criteria?
 - A. Pruritus, xerosis, and elevated IgE
 - B. Pruritus, flexural lichenification, and history of asthma
 - C. Recurrent conjunctivitis, xerosis, and pruritus
 - D. Pruritus, intolerance to wool, and itch when sweating
 - E. I'm not sure
3. With what percent of your patients with AD do you assess disease severity with measures such as Investigator's Global Assessment (IGA), POEM, or body surface area (BSA) at each visit?
 - A. 0% of patients
 - B. 1% - 25% of patients
 - C. 26% - 50% of patients
 - D. 51% - 75% of patients
 - E. 76% - 100% of patients
4. With what percent of your patients with AD do you use the POEM assessment scale to determine and track disease severity and response to treatment at each visit?
 - A. 0% of patients
 - B. 1% - 25% of patients
 - C. 26% - 50% of patients
 - D. 51% - 75% of patients
 - E. 76% - 100% of patients
5. Which of the following represents the POEM score range for severe eczema?
 - A. 3-7
 - B. 8-16
 - C. 17-24
 - D. 25-28
 - E. I'm not sure
6. Which of the following statements is true regarding dupilumab, according to phase 3 studies of patients with AD?
 - A. It improved pruritus but not POEM scores
 - B. It improved POEM scores but not pruritus
 - C. It improved neither pruritus nor POEM scores
 - D. It improved both pruritus and POEM scores
 - E. I'm not sure
7. Which of the following statements is true regarding crisaborole, according to phase 3 studies of patients with AD?
 - A. It improved pruritus but not quality of life
 - B. It improved quality of life but not pruritus
 - C. It improved neither pruritus nor quality of life
 - D. It improved both pruritus and quality of life
 - E. I'm not sure

Post-Test

Atopic Dermatitis: You Can't Improve What You Don't Measure

Live Symposium – Wednesday, November 14, 2018

Participants are required to complete the pre-survey and post-test to assess their achievement of the educational objectives for this activity. You must complete both this pre-survey and post-test as well as the evaluation and credit request form to receive credit. A score of 75% is required for credit.

- Now, how confident are you in your ability to utilize the Hanifin and Rajka criteria and/or the AAD criteria to aid in the diagnosis of AD in clinical practice?
 - Extremely confident
 - Confident
 - Somewhat confident
 - Not confident at all
- Which of the following best characterizes a patient with 3 of the major criteria of the Hanifin and Rajka criteria?
 - Pruritus, xerosis, and elevated IgE
 - Pruritus, flexural lichenification, and history of asthma
 - Recurrent conjunctivitis, xerosis, and pruritus
 - Pruritus, intolerance to wool, and itch when sweating
- Now, with what percent of your patients with AD will you assess disease severity with measures such as Investigator's Global Assessment (IGA), POEM, or body surface area (BSA) at each visit?
 - 0% of patients
 - 1% - 25% of patients
 - 26% - 50% of patients
 - 51% - 75% of patients
 - 76% - 100% of patients
- Now, with what percent of your patients with AD will you use the POEM assessment scale to determine and track disease severity and response to treatment at each visit?
 - 0% of patients
 - 1% - 25% of patients
 - 26% - 50% of patients
 - 51% - 75% of patients
 - 76% - 100% of patients
- Which of the following represents the POEM score range for severe eczema?
 - 3-7
 - 8-16
 - 17-24
 - 25-28
- Which of the following statements is true regarding dupilumab, according to phase 3 studies of patients with AD?
 - It improved pruritus but not POEM scores
 - It improved POEM scores but not pruritus
 - It improved neither pruritus nor POEM scores
 - It improved both pruritus and POEM scores
- Which of the following statements is true regarding crisaborole, according to phase 3 studies of patients with AD?
 - It improved pruritus but not quality of life
 - It improved quality of life but not pruritus
 - It improved neither pruritus nor quality of life
 - It improved both pruritus and quality of life